Pre-chemotherapy hemoglobin levels and survival in patients with advanced epithelial ovarian cancer who received a first-line taxane/platinum-based regimen: Results of a multicenter retrospective Italian study

Angiolo Gadducci, Enrico Sartori, Fabio Landoni, Paolo Zola, Tiziano Maggino, Nicoletta Colombo, Antonio Fanucchi, Francesca Chiudinelli, Mariateresa LaPresa, Anna Maria Ferrero

Research output: Contribution to journalArticlepeer-review

Abstract

Objective. The aim of this retrospective multicenter study was to assess whether the pre-chemotherapy hemoglobin levels have any impact on the clinical outcome of patients with advanced epithelial ovarian cancer who received a first-line taxane/platinum-based regimen. Methods. The study was conducted on 315 patients who underwent initial surgery followed by taxane/platinum-based chemotherapy for FIGO stage IIc-IV epithelial ovarian cancer. All the patients had ECOG performance status 0-1 at presentation. The median follow-up of survivors was 36 months (range, 6-120 months). Results. The 25%, 50%, and 75% quantiles of hemoglobin levels before starting first-line chemotherapy were 10.2, 11.4, and 12.3 g/dl, respectively. Residual disease after initial surgery (>1 cm versus ≤1 cm, P = 0.0013) was the only independent prognostic variable for overall survival. Conversely, hemoglobin levels (12.3 g/dl) were inversely related to overall survival at univariate (P = 0.03) but not at multivariate analysis. Conclusions. This investigation showed that hemoglobin levels before starting first-line taxane/platinum-based chemotherapy are not an independent prognostic factor for overall survival in patients with advanced epithelial ovarian cancer.

Original languageEnglish
Pages (from-to)118-123
Number of pages6
JournalGynecologic Oncology
Volume98
Issue number1
DOIs
Publication statusPublished - Jul 2005

Keywords

  • Anemia
  • Carboplatin
  • Chemotherapy
  • Cisplatin
  • Hemoglobin
  • Ovarian cancer
  • Paclitaxel

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Fingerprint Dive into the research topics of 'Pre-chemotherapy hemoglobin levels and survival in patients with advanced epithelial ovarian cancer who received a first-line taxane/platinum-based regimen: Results of a multicenter retrospective Italian study'. Together they form a unique fingerprint.

Cite this